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ABSTRACT
Evidence has accumulated indicating that LHRH might behave as
an autocrine/paracrine growth inhibitory factor in some peripheral
tumors. However, LHRH receptors in tumor cells have not been fully
characterized, so far. The present experiments were performed to
analyze: 1) the messenger RNA expression; 2) the molecular size; and
3) the signal transduction pathway of LHRH receptors in prostate
cancer. For these studies, the human androgen-dependent LNCaP
and androgen-independent DU 145 prostate cancer cell lines were
used. 1) By RT-PCR, a complementary DNA product, which hybrid-
ized with a 32P-labeled oligonucleotide probe specific for the pituitary
LHRH receptor complementary DNA, was found both in LNCaP and
in DU 145 cells. 2) Western blot analysis, using a monoclonal antibody
raised against the human pituitary LHRH receptor, revealed the
presence of a protein band of approximately 64 kDa (corresponding to
the molecular mass of the pituitary receptor) in both cell lines. 3) In
LNCaP and DU 145 cells, pertussis toxin completely abrogated the
antiproliferative action of a LHRH agonist (LHRH-A). Moreover,
LHRH-A substantially antagonized the pertussis toxin-catalyzed
ADP-ribosylation of a Gai protein. Finally, LHRH-A significantly
counteracted the forskolin-induced increase of intracellular cAMP
levels in both cell lines. These data demonstrate that the LHRH
receptor, which is present in prostate cancer cells, independently of
whether they are androgen-dependent or not, corresponds to the pi-
tuitary receptor, in terms of messenger RNA expression and protein
molecular size. However, at variance with the receptor of the go-
nadotrophs, prostate cancer LHRH receptor seems to be coupled to the
Gai protein-cAMP signal transduction pathway, rather than to the
Gaq/11-phospholipase C signaling system. This might be responsible
for the different actions of LHRH in anterior pituitary and in prostate
cancer. (Endocrinology 140: 5250–5256, 1999)
THE HYPOTHALAMIC LHRH, by stimulating gonado-tropin synthesis and release, is the key hormone in the
regulation of reproduction (1–4). The neurohormone specif-
ically binds to high-affinity pituitary receptors, which belong
to the seven-transmembrane domain family and are coupled
to the pertussis toxin (PTX) insensitive Gaq/G11 protein and
to the phospholipase C signaling pathway (5–7).
In recent years, evidence has been accumulated indicating
that LHRH might be present in a variety of extrapituitary
tissues, both normal (8–11) and tumoral (12–17), where it
might act in an autocrine/paracrine fashion.
In line with these observations, we have previously
demonstrated that LHRH agonists exert a significant and
dose-dependent inhibitory action on the proliferation of
prostate cancer cells, either androgen-dependent or an-
drogen-independent, through the binding to specific re-
ceptors (18, 19). Moreover, we have found that a messen-
ger RNA (mRNA) coding for LHRH is expressed in these
cells, suggesting that the peptide is locally synthesized (19,
20). Taken together, these data indicate that an autocrine/
paracrine LHRH system is expressed also in prostate can-
cer tissue and that this system may participate in the local
regulation of tumor growth by inhibiting cell proliferation
(18 –20).
At the level of the tumoral prostate, LHRH receptors have
been studied, so far, mainly in terms of binding parameters
(i.e. affinity constant for LHRH analogs); however, divergent
results have been reported by the different authors (18, 19,
21–25).
The present experiments have been performed to better
characterize the LHRH receptor in prostate cancer. To this
purpose, we have analyzed the mRNA expression, the mo-
lecular size, and the signal transduction pathway of these
receptors in two cell lines [androgen-dependent (LNCaP)
and androgen-independent (DU 145)] derived from prostate
tumors.
Materials and Methods
Materials
The LHRH agonist Zoladex [D-Ser(tBu)6Aza-Gly-LHRH, LHRH-A]
was kindly donated by Zeneca Pharmaceuticals Divisione Farmaceutici
(Milan, Italy). PTX and GTP were purchased from Sigma Chemical Co.
(St. Louis, MO). 32P-NAD was obtained from NEN Life Science Products
(Boston, MA).
Received February 12, 1999.
Address all correspondence and requests for reprints to: Dr. P.
Limonta, Center for Endocrinological Oncology, Department of
Endocrinology, Via Balzaretti 9, 20133 Milano, Italy. E-mail: limonta@
mailserver.unimi.it.
* This work was supported by Associazione Italiana per la Ricerca sul
Cancro and by Ministero dell’Universita` e della Ricerca Scientifica e
Tecnologica.
0013-7227/99/$03.00/0 Vol. 140, No. 11
Endocrinology Printed in U.S.A.
Copyright © 1999 by The Endocrine Society
5250
Cell cultures
The cell lines LNCaP-FGC (Lymph Node Carcinoma of the Prostate-
Fast Growing Colony) and DU 145 were obtained from American Type
Culture Collection (Rockville, MD). Both cell lines (passages 27–35 for
LNCaP and 60–70 for DU 145) were routinely grown in RPMI-1640
medium (Seromed, Biochrom KG, Berlin, Germany) supplemented with
FBS (Life Technologies, Paisley, Scotland) (10% for LNCaP and 5% for
DU 145 cells), glutamine (1 mm) and antibiotics (100 IU/ml penicillin G
sodium, 100 mg/ml streptomycin sulfate) in a humidified atmosphere of
5% CO2-95% air. In these culture conditions, the duplication period is
48 h for LNCaP and 36 h for DU 145 cells, respectively.
Animals
Because of the impossibility of obtaining normal human pituitary in
our country, male rats have been used as positive (pituitary) and as
negative (skeletal muscle) controls in Western blot analysis of LHRH
receptors.
Adult male Sprague Dawley rats were obtained from Charles River
Laboratories, Inc. (Calco, Como, Italy). Animals were maintained on a
14-h light, 10-h dark schedule, with standard pellet food and water
available ad libitum. All rats were killed by decapitation; tissues were
quickly collected and frozen at 270 C until Western blot analysis.
RT-PCR analysis of LHRH receptor mRNA
Total RNA from LNCaP and DU 145 cell lines was prepared accord-
ing to a modification of the guanidium thiocyanate/cesium chloride
method (26). RNA (2 mg) from each sample was used in a RT reaction.
Complementary DNA (cDNA) synthesis was performed using the Gene
AMP kit (Perkin-Elmer Corp. Cetus, Norwalk, CT), with an oligo(dT)16
as a primer for the reverse transcriptase. Samples containing cDNAs
obtained from prostate tumor cells were then amplified in a 100-ml
solution containing PCR buffer (50 mm KCl, 10 mm Tris-HCl), 2 mm
MgCl2, 0.15 mm of a pair of specific primers, and 2.5 U Taq polymerase.
Amplification was carried out for 35 cycles (1-min denaturation at 94 C,
1-min primer annealing at 50 C, and 3-min primer extension at 72 C). The
primers were synthesized, based on the reported sequence of the human
pituitary LHRH receptor cDNA (27). The primers used were: sense
59-GCTTGAAGCTCTGTCCTGGGA-39 (225 to 25) and antisense 59-
CCTAGGACATAGTAGGG-39 (844–860). These primers have been pre-
viously used by Kakar et al. (14) to detect the presence of LHRH receptor
mRNA in human extrapituitary tissues. After PCR, the amplified cDNA
products were separated on a 1.5% agarose gel and stained with
ethidium bromide. Southern blot analysis was performed as described
(28). Blots were hybridized with a synthetic 32P-labeled oligonucleotide
probe (19 mer) specific for a sequence (nucleotides 392/410) of the
human pituitary LHRH receptor cDNA.
Western blot analysis of the LHRH receptor
Membrane fractions were prepared from rat pituitaries and skeletal
muscle, from LNCaP, and from DU 145 cells, according to the protocol
reported by Karande et al. (29), with some modifications. Samples were
homogenized in 10 mm Tris-HCl (pH 7.6) buffer containing 1 mm di-
thiothreitol on ice. The homogenates were centrifuged two times for 10
min each at 800 3 g to remove cellular debris, and the resulting super-
natants were centrifuged at 18,000 3 g to pellet down the membrane
fractions. The pellets were solubilized in RIPA buffer [50 mm Tris-HCl
(pH 7.7), 150 mm NaCl, 0.8% Triton X-100, 0.8% sodium deoxycholate,
0.08% SDS, 10 mm ethylendiamine tetraacetate, 100 mm Na3VO4, 50 mm
NaF, 0.3 mm phenylmethylsulfonylfluoride, and 5 mm iodoacetic acid]
and electrophoresed on 10% polyacrylamide gel under reducing con-
ditions. Proteins were transferred onto a nitrocellulose filter, in 25 mm
Tris-HCl (pH 8.3), 92 mm glycine, and 20% methanol at 30 V overnight.
Filters were probed with the F1G4 monoclonal antibody raised against
the human pituitary LHRH receptor (kindly provided by Dr. A. A.
Karande, Department of Biochemistry, Indian Institute of Science, Ban-
galore, India), followed by incubation with an antimouse IgG. Antobody
bound to the LHRH receptor was detected with the ECL-Western blot-
ting detection system after a 5- to 10-min exposure to a Hyperfilm-ECL
x-ray film (Amersham Pharmacia Biotech, Milan, Italy), at room tem-
perature (30). The specificity of F1G4 antibody for the human pituitary
LHRH receptor has been previously demonstrated (29).
Cell proliferation studies
LNCaP and DU 145 cells were plated at a density of 5,000 and 500
cells/cm2, respectively, in 6-mm dishes in standard culture medium.
Cells were allowed to attach and start growing for 3 days; the seeding
media were then changed to experimental media. Cells were treated, for
7 days, with LHRH-A (1 mm) either in the absence or in the presence of
PTX (25 ng/ml for LNCaP and 50 ng/ml for DU 145 cells); the medium
was changed every 2 days. At the end of the treatment, cells were
collected and counted by hemocytometer. The dose of LHRH-A selected
for this and the following experiments has been chosen on the basis of
previous papers from our laboratory analyzing the interaction between
LHRH and stimulatory growth factors in prostate cancer cells (31, 32).
ADP-ribosylation
ADP-ribosylation was carried out as described (33). Briefly, isolated
plasma membranes (0.5 mg/ml) from LNCaP and DU 145 cells were
incubated with PTX (2 mg/ml) in 20 mm Tris-HCl, pH 7.5, containing 1
mm ATP, 0.1 mm GTP, 1 mm EDTA, 1 mm dithiothreitol, 10 mm thy-
midine, 10 mm 32P-NAD (5 3 106 cpm/nmol), either in the absence or
in the presence of LHRH-A (1 mm), in a final vol of 200 ml. After
incubation for 30 min at 37 C, the reaction was terminated by the
addition of 1 ml ice-cold 20 mm Tris-HCl, pH 7.5. Membranes were
pelleted by centrifugation and washed twice with the same buffer.
Membrane proteins were solubilized in Laemmli’s SDS sample buffer
and resolved by 12% PAGE. After electrophoresis, gels were dried, and
ADP-ribosylated proteins were detected by autoradiography.
Western blot analysis of Gai1 subunit protein
The polyclonal rabbit antiserum I1C, directed toward a synthetic
peptide corresponding to aminoacids 160–169 (only present in the Gai1
subunit) was kindly donated by G. Milligan (Division of Biochemistry
and Molecular Biology, University of Glasgow, Glasgow, Scotland, UK)
(34). Membrane preparations, protein separation, and electrophoretic
transfer to nitrocellulose filters were performed as described under
Western blot analysis of LHRH receptors. Blots were incubated overnight
at 4 C in TBST buffer (20 mm Tris-HCl, pH 7.5, 150 mm NaCl, 0.1% Tween
20) containing 5% powdered skim milk. After five washes with TBST,
membranes were incubated for 3 h at room temperature with I1C pri-
mary antibody diluted in milk/TBS and for 1.5 h with horseradish
peroxidase-conjugated goat antirabbit IgG. Proteins were detected using
the SuperSignal detection kit (Pierce Chemical Co., Rockford, IL).
cAMP determination
LNCaP and DU 145 cells were plated at a density of 30,000 cells/cm2
in 24-multiwell plates. After 2 days, cells were washed with 1 ml serum-
free medium, pretreated with 3-isobutyl-1-methylxantine (0.5 mm) (Sig-
ma Chemical Co.) for 15 min at 37 C and then treated with forskolin (FSK,
5 mm), either alone or in the presence of LHRH-A (1 mm), for 15 min at
37 C. After the treatment, cells were extracted with ethanol 65% at 4 C
for 5 min, two times, and centrifuged for 3 min (10,000 3 g). The
supernatants were collected, dried, and stored at 220 C. cAMP content
in each sample was determined by the 3H-cAMP assay system (Amer-
sham Pharmacia Biotech), according to the manufacturer’s instructions.
Statistical analysis
The data from experiments involving cell proliferation and cAMP
determination were analyzed according to Dunnett’s test (35) after one-
way ANOVA.
Results
Expression of the LHRH receptor
The results obtained, by RT-PCR with the appropriate
probes, demonstrate that the predicted 885-bp cDNA frag-
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ment (Fig. 1A) was obtained both in LNCaP (lane 1) and in
DU 145 (lane 2) cells. Negative control samples without RT
did not give rise to any detectable product (lane 3), ruling out
the possibility of genomic DNA contamination. Gels were
Southern blotted and hybridized with a synthetic 32P-labeled
oligonucleotide probe specific for the pituitary LHRH re-
ceptor cDNA. The cDNA fragments obtained from LNCaP
and DU 145 cells specifically hybridized with the labeled
probe (Fig. 1B, lanes 1 and 2). No hybridization signal was
found in the negative control (Fig. 1B, lane 3).
Molecular size of the LHRH receptor protein
The presence of a protein corresponding to the LHRH
receptor has been investigated by Western blotting in pros-
tate tumor cells by means of the F1G4 monoclonal antibody
specifically raised against the human pituitary LHRH recep-
tor. As shown in Fig. 2, a major protein band of approxi-
mately 64 kDa molecular mass is identified by the antibody
both in LNCaP and in DU 145 cells (lanes 1 and 2, respec-
tively). This molecular size corresponds to that reported for
the human pituitary LHRH receptor (29, 36). Fig. 3 (lanes 3
and 4) confirms the presence of a 64-kDa protein binding the
F1G4 antibody in prostate cancer cell lines. Moreover, Fig. 3
(lane 1) also shows that, in rat pituitary protein preparations,
the antibody identified a band of approximately 60 kDa; this
molecular mass corresponds to that previously described by
Wormald et al. (36) for the rat pituitary LHRH receptor. No
binding of the F1G4 antibody to protein preparations from
rat skeletal muscle samples could be detected (Fig. 3, lane 2).
Effect of PTX on the antiproliferative action of LHRH-A
Preliminary experiments performed in our laboratory had
indicated that the treatment of prostate cancer cells with
LHRH-A did not affect phosphoinositide turnover or intra-
cellular Ca21 levels (unpublished observations), suggesting
that, in these cells, LHRH receptors might not be coupled to
the Gaq/11-phospholipase C system as occurs at the pituitary
level. Therefore, we hypothesized that, in these cells, the
antiproliferative action of LHRH agonists might be mediated
by the Gai-cAMP signal transduction pathway. It is known
that PTX, through ADP-ribosylation of Gai proteins, impairs
the receptor-effector interaction (37). Therefore, we have
FIG. 1. Amplification of LHRH receptor cDNAs from LNCaP (lane 1)
and DU 145 (lane 2) cells. Lane 3, No RT; lane 4, RT-PCR control (308
bp); lane 5, DNA molecular weight marker III (Roche Diagnostics,
Monza, Italy); A, ethidium bromide stained agarose gel of the am-
plified cDNAs; B, autoradiography of the Southern blot obtained from
the gel shown in A after hybridization with a 32P-labeled oligonucle-
otide human LHRH receptor probe. One experiment representative of
three is reported.
FIG. 2. Western blot analysis of solubilized membrane proteins from
LNCaP (lane 1) and DU 145 (lane 2) cells, probed with the F1G4
monoclonal antibody raised against the human pituitary LHRH re-
ceptor. One experiment representative of three is reported.
FIG. 3. Western blot analysis of solubilized membrane proteins from
rat pituitary (lane 1), rat skeletal muscle (lane 2), LNCaP cells (lane
3), and DU 145 cells (lane 4), probed with the F1G4 monoclonal
antibody raised against the human pituitary LHRH receptor. Only
the bands of interest (60–64 kDa) are shown. One experiment rep-
resentative of four is reported.
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studied whether PTX might interfere with the antimitogenic
action of LHRH-A. As expected, the LHRH agonist signifi-
cantly inhibited LNCaP cell growth (Fig. 4A), around 30% in
the experiments here reported. In previous studies, we have
demonstrated that this antiproliferative action is specific,
because it can be blocked by a second-generation antagonist
(Nal-Arg-LHRH) (18, 19). More recently, third-generation
antagonists have been reported to act as agonists in this and
in similar experiments (38, 39). Fig. 4 also shows that the
treatment with PTX alone did not affect cell proliferation. On
the other hand, when PTX and LHRH-A were given together,
PTX completely prevented the antiproliferative action of the
LHRH agonist (Fig. 4A). Similar results were obtained in DU
145 cells (Fig. 4B).
Effect of LHRH-A on PTX-induced ADP-ribosylation
The preceding observation that PTX significantly coun-
teracts the antiproliferative action of LHRH-A suggests that
the LHRH agonist might act through a Gai protein. To fur-
ther confirm this hypothesis, we investigated whether
LHRH-A might affect PTX-induced ADP-ribosylation of the
Gai protein. As expected, incubation of prostate cancer cell
membranes with PTX, in the presence of 32P-NAD, brought
about ADP-ribosylation of a 41-kDa Gai protein in both
LNCaP and DU 145 cells (Fig. 5, A and B; lane 1). LHRH-A
substantially counteracted the transfer of 32P-ADP-ribose to
the Gai protein in the two cell lines (Fig. 5, A and B; lane 2).
Detection of Gai proteins
The presence of Gai subunit proteins in prostate cancer
cells was evaluated by Western blot analysis. Fig. 6 shows
that, after immunoblotting with the specific antibody, the
41-kDa Gai1 subunit could be detected in LNCaP as well as
in DU 145 cells and suggests that this specific Gai protein
subunit might mediate LHRH activity in prostate cancer
cells. In these studies, Western blot analysis has been per-
formed with an antibody specifically recognizing the 41-kDa
Gai1 protein subunit. Obviously, the possibility that addi-
tional Gai subunits might be present (and/or coupled to the
LHRH receptor) in prostate cancer cells cannot be ruled out.
It is not surprising to find that the amounts of Gai1 protein
seem different in LNCaP and in DU 145 cells. This and other
G proteins are not exclusively linked to the LHRH receptor;
they may represent the beginning of the signaling pathways
for other growth regulatory mechanisms that have not been
investigated in the present study.
Effects of LHRH-A on cAMP accumulation
Activation of Gai subunit proteins is negatively correlated
with cAMP production. To further confirm that, in prostate
cancer cells, LHRH receptors might be coupled to Gai pro-
teins, we studied the effects of LHRH-A on FSK-induced
cAMP accumulation, both in LNCaP and in DU 145 cells. In
LNCaP cells (Fig. 7A), LHRH-A, when given alone, did not
affect cAMP levels. FSK, as expected, substantially stimu-
lated cAMP accumulation. LHRH-A significantly counter-
FIG. 4. Effects of PTX on the antiproliferative action of LHRH-A (1
mM) in LNCaP (A) and in DU 145 (B) cells. Each experimental group
consisted of six replicates. Each experiment was repeated three times,
with identical results. Results are expressed as the mean cell number
per plate 6 SE. C, Controls without drug; *, P , 0.05 vs. C.
FIG. 5. Effects of LHRH-A (1 mM) on the PTX-induced ADP-ribo-
sylation in membranes from LNCaP (A) and DU 145 (B) cells. Plasma
membranes from prostate cancer cells were reacted with 32P-NAD
and PTX in the absence (lane 1) or in the presence of LHRH-A (lane
2). Shown are representative profiles of three separate experiments
that gave identical results.
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acted the increase in cAMP levels induced by FSK, an effect
which could be blocked by a second-generation antagonist
(Nal-Arg-LHRH, 1028 m) (data not shown). Similar results
were obtained in DU 145 cells (Fig. 7B).
Discussion
The properties of LHRH receptors have been analyzed in
two prostate tumor cell lines (one androgen-dependent,
LNCaP, and the other one androgen-independent, DU 145)
by evaluating their mRNA expression, their molecular size,
and their signal transduction pathway(s).
The data obtained show, by RT-PCR, that a mRNA coding
for the LHRH receptor can be detected in LNCaP as well as
in DU 145 cells. In line with this observation, the expression
of the mRNA for LHRH receptors has been previously re-
ported in some peripheral tumors, such as breast, endome-
trial, and ovarian cancers (13–17).
In LNCaP and in DU 145 cells, the mRNA is further trans-
lated into a receptor protein. This is based on the observation
that both cell lines, when analyzed by Western blot using a
monoclonal antibody raised against the human pituitary
LHRH receptor, reveal the presence of a protein of the same
molecular size of the receptor found in normal human go-
nadotrophs (64 kDa) (29, 36).
The present data, obviously, do not exclude that the gene
coding for this protein might have undergone a mutation and
that, consequently, the protein, even with the same molec-
ular size, might present some deviation from the classical
receptor. This would be in line with the reports from us and
from others showing that the binding affinity of the receptor
in prostate and in other tumoral tissues might be significantly
lower than that observed in the pituitary (18, 19, 22, 40, 41).
Because of the findings by Kakar et al. (14) and those here
reported, which have used the same methodology, one
would expect the eventual mutation to reside outside the
885-bp fragment amplified by Kakar et al. (14) and in the
present work.
Some doubts have been raised on the ability of the anti-
body used in the experiments here reported to recognize the
authentical LHRH receptor protein. This argument may be
counteracted by the following considerations. First, this an-
tibody fully recognizes the 29-amino acid peptide, corre-
sponding to the N-terminal portion of the LHRH receptor
protein, which has been used to raise it (29). Moreover, in
immunohistochemical studies, the antibody stains clusters of
cells in the human pituitary. This staining is specific, because
the reaction can be stopped by a preincubation of the anti-
body with an excess of the antigenic peptide before incuba-
tion with the tissue section (29). By Western blot analysis, the
antibody will recognize the typical 64-kDa band of the LHRH
receptor in human pituitary (29), as well as in human pla-
centa and in breast carcinoma (A. A. Karande, personal com-
munication) membrane proteins. The same band will also
bind a 125I-labeled LHRH, showing its ability to act as a full
receptor. Finally, by immunohistochemistry, COS-7 cells
transfected with the LHRH receptor cDNA show a specific
positive staining to the monoclonal antibody (A. A. Karande,
personal communication).
At the pituitary level, LHRH receptors are coupled, via the
Gaq/G11 group of G proteins, to PLC (5–7). The data here
reported indicate that, in prostate tumor cells, the LHRH
receptor is linked to Gai proteins which, through the inhi-
bition of cAMP accumulation, probably mediate the anti-
proliferative action of the peptide. These conclusions are
FIG. 6. Western blot analysis of solubilized membrane proteins from
LNCaP and DU 145 cells probed with the polyclonal I1C antibody
raised against the Gai1 protein. One experiment representative of
three is reported.
FIG. 7. Effects of LHRH-A (1 mM) on FSK (5 mM)-induced cAMP ac-
cumulation in LNCaP (A) and in DU 145 (B) cells. Each experimental
group consisted of six replicates. Each experiment was repeated three
times, with identical results. Results are expressed as the mean cAMP
pmoles per well 6 SE. *, P , 0.05 vs. FSK.
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based on the following observations: 1) treatment with PTX
counteracts the antiproliferative action of LHRH agonists; 2)
LHRH agonists cause a profound reduction in the PTX-
mediated ADP-ribosylation of a membrane protein of rela-
tive molecular mass 41 kDa corresponding to Gai1, as re-
vealed by Western blot analysis, performed using a specific
antibody; 3) LHRH agonists significantly counteract FSK-
induced increase of intracellular cAMP levels. In the authors’
opinion, this is the first demonstration of the coupling of the
LHRH receptor to the Gai-cAMP signal transduction path-
way in prostate cancer, in addition to the identification of the
molecular size of the LHRH receptor protein (see above). In
line with the present data, Imai and co-workers (42) have
recently reported that, in tumors of the human female re-
productive tract, LHRH receptors are coupled to a 41-kDa
Gai protein; these authors suggested that this protein might
mediate the LHRH-induced phosphotyrosine phosphatase
activity in tumor cells (42, 43).
We failed to observe any change in phosphoinositide me-
tabolism and/or Ca21 levels in prostate cancer cells after the
treatment with LHRH agonists (unpublished observations),
which inhibit cell proliferation; this suggests that the LHRH
receptor might not be linked to the Gaq/11-PLC system in
these cells. In agreement with our observations, Emons and
co-workers (44) have shown that, in human ovarian and
endometrial cancer cells, the LHRH agonist triptorelin, at
concentrations that are clearly inhibitory on cell prolifera-
tion, does not affect PLC or PKC activity. However, at vari-
ance with these observations, LHRH agonists have been re-
ported to stimulate PLC activity in other types of tumors,
such as rat (45) and human (46) mammary tumors, as well
as human ovarian cancers (47). Therefore, the possible in-
volvement of the Gaq/11 signaling system in the antimito-
genic action of LHRH still remains an open question and,
certainly, needs further studies.
Taken together, the present data strongly indicate that, in
prostate tumor cells, the LHRH receptor is expressed and
corresponds to the pituitary LHRH receptor, in terms of
molecular weight. Interestingly, the signal transduction
pathway of this receptor (Gai-cAMP pathway) seems to be
different from that of the same receptors at pituitary level
(Gaq/11-PLC system) (Fig. 8). This fact might be responsible
for the different actions of LHRH in peripheral tumors and
in the anterior pituitary. In gonadotrophs, LHRH receptor-
coupled Gaq/11 proteins mediate the stimulatory action of
the hypothalamic hormone on gonadotropin synthesis and
release (5–7). In prostate cancer cells, on the contrary, LHRH
may behave as an inhibitory autocrine/paracrine factor,
which exerts its antimitogenic action through the activation
of Gai proteins, negatively coupled to the c-AMP intracel-
lular signaling pathway. It is noteworthy, in this context, that
LHRH receptor mRNA, molecular size, and signal transduc-
tion pathway seem to be the same in androgen-dependent
and androgen-independent prostate cancer cells.
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FIG. 8. Schematic representation of the suggested signal transduction pathway linked to the LHRH receptor in prostate cancer cells. IP3,
Inositoltriphosphate; DAG, diacylglycerol.
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